- Bright Minds Biosciences (DRUG) appoints industry experts for key roles and expands the scientific advisory team
- Jianmin Duan, PhD, Vice President, Pharmacology, will lead Bright Minds’ preclinical testing work
- Thomas Grizzle, Vice President, Toxicology, will lead Bright Minds’ efforts around the safety and biological effects of its therapeutics
- Krista Lanctot, PhD, Advisor, will join Bright Minds’ Scientific Advisory team
- Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain
- Bright Minds Biosciences (DRUG) is down 0.67 per cent and is trading at C$5.92 at 12:16 pm ET
Bright Minds Biosciences (DRUG) today announced two additions to its leadership team and one new scientific advisor.
Jianmin Duan, PhD, Vice President, Pharmacology, will lead Bright Minds’ preclinical testing work.
Thomas Grizzle, Vice President, Toxicology, will lead Bright Minds’ efforts around the safety and biological effects of its therapeutics.
Krista Lanctot, PhD, Advisor, will join Bright Minds’ Scientific Advisory team.
“The additions of Jianmin, Tom, and Krista to the Bright Minds team will help us to accelerate the advancement of our development pipeline as we broaden our core scientific strengths,” stated Ian McDonald, Chief Executive Officer of Bright Minds.
“Each of these talented individuals brings decades of experience that will help us progress our approach of using serotonin agonists to develop improved therapeutics to address a variety of mental health, epilepsy, and pain management needs,” added McDonald.
Jianmin Duan, PhD, is an experienced pharmaceutical research and development scientist with expertise in drug absorption, distribution, metabolism, excretion, pharmacokinetics and pharmacology.
Previously, Dr. Duan spent more than 20 years at Boehringer Ingelheim (Canada) Ltd. in roles of increasing responsibility, most recently as Director, Preclinical ADMEPK/Pharmacology.
He has authored more than 50 papers that have appeared in peer-reviewed journals and holds three patents.
Thomas Grizzle is an experienced toxicologist, specializing in pharmacokinetics; safety pharmacology; absorption, distribution, metabolism, and excretion (ADME); bioanalytical chemistry; project management; and report writing.
Prior to establishing his consultancy, he was a Senior Toxicologist at Icagen, Inc. and Triangle Pharmaceuticals.
Her research interests include optimizing the treatment of neuropsychiatric symptoms associated with illness, including mood changes, apathy, aggression, and cognitive changes.
Dr. Lanctot’s broad experience includes running clinical trials for cognitive and neuropsychiatric symptoms associated with dementia.
Dr. Lanctot received a BSc in Pharmacology and Toxicology, an MS in Clinical Pharmacology and a PhD in Clinical Pharmacology from the University of Toronto.
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
Bright Minds Biosciences (DRUG) is down 0.67 per cent and is trading at C$5.92 at 12:16 pm ET.
